RESUMO
The most representative indicator of vitamin D status in clinical practice is 25(OH)D3, but new biomarkers could improve the assessment of vitamin D status and metabolism. The objective of this study is to investigate the association of serum vitamin D metabolites and vitamin D metabolite ratios (VMRs) with potentially influential factors in premenopausal women. This is a cross-sectional study based on 1422 women, aged 39-50, recruited from a Madrid Medical Diagnostic Center. Participants answered an epidemiological and a food frequency questionnaire. Serum vitamin D metabolites were determined using an SPE-LC-MS/MS platform. The association between participant's characteristics, vitamin D metabolites, and VMRs was quantified by multiple linear regression models. Mean 25(OH)D3 concentration was 49.2 + 18.9 nmol/L, with greater deficits among obese, nulliparous, dark-skinned women, and with less sun exposure. A lower R2 ratio (1,25(OH)2D3/25(OH)D3) and a higher R4 (24,25(OH)2D3/1,25(OH)2D3) were observed in nulliparous women, with high sun exposure, and those with low caloric intake or high consumption of calcium, vitamin D supplements, or alcohol. Nulliparous women had lower R1 (25(OH)D3/Vit D3) and R3 (24,25(OH)2D3/25(OH)D3), and older women showed lower R3 and R4. Vitamin D status modified the association of the VMRs with seasons. VMRs can be complementary indicators of vitamin D status and its endogenous metabolism, and reveal the influence of certain individual characteristics on the expression of hydroxylase enzymes.
Assuntos
Metaboloma , Pré-Menopausa/sangue , Vitamina D/sangue , Adulto , Feminino , Humanos , Pessoa de Meia-IdadeRESUMO
Epidemiological studies suggest that high intake of soy isoflavones may protect against breast cancer, but causal relationships can only be established by experimental trials. Thus, we aimed to provide a systematic review of randomized controlled trials (RCTs) on the effect of an isoflavone intake on risk factors of breast cancer in healthy subjects. After a systematic literature search in PubMed, 18 different RCTs with pre- and/or postmenopausal women were included and investigated for details according to the PRISMA guideline. In these studies, isoflavones were provided by soy food or supplements in amounts between 36.5-235 mg/d for a period of 1-36 months. Breast density, estrogens including precursors, metabolites, estrogen response such as length of menstrual cycle, and markers of proliferation and inflammation were considered. However, in most studies, differences were not detectable between isoflavone and control/placebo treatment despite a good adherence to isoflavone treatment, irrespective of the kind of intervention, the dose of isoflavones used, and the duration of isoflavone treatment. However, the lack of significant changes in most studies does not prove the lack of effects as a sample size calculation was often missing. Taking into account the risk of bias and methodological limitations, there is little evidence that isoflavone treatment modulates risk factors of breast cancer in pre- and postmenopausal women. Future studies should calculate the sample size to detect possible effects and consider methodological details to improve the study quality.
Assuntos
Neoplasias da Mama/prevenção & controle , Dieta/métodos , Ingestão de Alimentos/fisiologia , Isoflavonas/administração & dosagem , Alimentos de Soja , Adulto , Idoso , Viés , Neoplasias da Mama/etiologia , Dieta/efeitos adversos , Suplementos Nutricionais , Feminino , Humanos , Pessoa de Meia-Idade , Pós-Menopausa/sangue , Pré-Menopausa/sangue , Ensaios Clínicos Controlados Aleatórios como Assunto , Fatores de RiscoRESUMO
OBJECTIVE: The aim of this study was to examine the effect of acupuncture on obesity-related parameters with regard to metabolomics. METHODS: This two-arm parallel, patient- and assessor-blind, sham-controlled randomized clinical trial included 120 obese participants. Participants were randomized into two groups. The treatment group received a combined intervention of manual acupuncture (MA) plus electroacupuncture (EA), while the control group received a combination of sham acupuncture interventions consisting of sham MA plus sham EA for 6 weeks. The serum lipid levels were measured as the primary outcome measure and anthropometric parameters and serum metabolic profiles including amino acids and carnitines were measured as secondary outcome measures. RESULTS: The serum lipid levels and anthropometric measurements did not significantly differ between groups, while body weight, body mass index (BMI), and waist circumference were improved within each group and the level of high-density lipoprotein cholesterol increased over time in the treatment group. There were no significant differences in amino acid levels between groups, while certain carnitine (C2, C4, C6, and l-carnitine) levels were significantly increased (p < 0.05) in the treatment group compared to the control group. CONCLUSION: In summary, 6 weeks of acupuncture treatment did not affect anthropometric and serum metabolic parameters, with the exception of certain carnitines, when compared to sham acupuncture. The observation of increased carnitine levels in the acupuncture group could result in potential long-term benefits to obese individuals. Additional studies are needed to investigate the long-term effects of acupuncture on lipid metabolism and the underlying mechanism of action. TRIAL REGISTRATION NUMBER: This study is registered at ClinicalTrials.gov (NCT02066090).
Assuntos
Terapia por Acupuntura , Obesidade/terapia , Sobrepeso/terapia , Pré-Menopausa/sangue , Adulto , Aminoácidos/sangue , Antropometria , Carnitina/sangue , Eletroacupuntura , Feminino , Humanos , Pessoa de Meia-Idade , Obesidade/sangue , Sobrepeso/sangue , Estudos Prospectivos , Resultado do TratamentoRESUMO
Owing to hormonal changes, women experience various psychophysiological alterations over a wide age range, which may result in decreased quality of life as well as in increased risks of diseases, such as cardiovascular diseases. Although studies have been performed to research complementary methods, such as meditation, the research field still requires an adequate amount of studies for public health guidelines. This pilot cross-sectional study aims to investigate a potential association of meditation with menopausal symptoms and blood chemistry for healthy women. In this study, data of 65 healthy women (age range 25-67) including 33 meditation practitioners and 32 meditation-naïve controls were analyzed to compare the Menopausal Rating Scale scores and blood chemistry with 7 more dropouts in the blood chemistry. For blood chemistry, nine components including glucose (GLU) and high-density lipoprotein cholesterol (HDL) were measured. Two-way analysis of variance was performed by dividing the total participants into 2 groups: premenopausal and postmenopausal participants. Compared to the control group, the meditation group showed a trend of reductions in the Menopausal Rating Scale total score (Pâ=â.054) and its 2 subcomponents: depressive mood (Pâ=â.064) and irritability (Pâ=â.061). In HDL level, there was a significant interaction between group and menopausal state (Pâ=â.039) with following post hoc results: among the premenopausal participants, a significant increase in the meditation group compared to the control group (Pâ=â.005); among the control group, a significant increase in the postmenopausal compared to the premenopausal participants (Pâ=â.030). In GLU level, there was a mild interaction between group and menopausal state (Pâ=â.070) with following post hoc results: among the postmenopausal participants, a trend of increase in the control group compared to the meditation group (Pâ=â.081); among the control group, a significant increase in the postmenopausal compared to the premenopausal participants (Pâ=â.040). Our research suggests a potential association of practicing meditation with alleviations in menopausal symptoms and changes in blood chemistry, warranting further studies with a longitudinal study design and larger populations to understand the underlying causal relationships.
Assuntos
Análise Química do Sangue/métodos , Meditação/métodos , Menopausa/sangue , Menopausa/psicologia , Adulto , Glicemia , Estudos de Casos e Controles , HDL-Colesterol/sangue , Estudos Transversais , Feminino , Voluntários Saudáveis , Humanos , Menopausa/fisiologia , Pessoa de Meia-Idade , Pós-Menopausa/sangue , Pós-Menopausa/psicologia , Pré-Menopausa/sangue , Pré-Menopausa/psicologia , Qualidade de VidaRESUMO
(1) Aim: the aim of this secondary analysis was to report the variability in response to n-3 long chain polyunsaturated fatty acids (LCPUFA) supplementation in erythrocytes, plasma and whole blood of a previously published dose response study. (2) Methods: a randomized, double-blind, placebo-controlled trial of parallel design was conducted, whereby pre-menopausal women were randomly assigned to consume 0, 0.35, 0.7 or 1 g/day of supplemental eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA). Fasted blood samples were taken at baseline and after eight weeks intervention. Erythrocyte, plasma and whole blood fatty acids were extracted using the method of Lepage and Roy and analysed using gas chromatography. (3) Results: There were significant increases in EPA plus DHA levels in the 0.7 g and 1 g dose groups, with the highest increase with the 1 g dose notably: in erythrocytes (from 5.69% to 7.59%), plasma (from 2.94% to 5.48%) and in whole blood (from 3.81% to 6.03%). There was high variability in response to the supplement in erythrocytes, plasma and whole blood across the different doses. (4) Conclusion: there is high individual variability in n-3 LCPUFA levels in response to n-3 LCPUFA supplementation, which should be taken into account in clinical trials using n-3 LCPUFA supplements.
Assuntos
Suplementos Nutricionais , Ácidos Docosa-Hexaenoicos/sangue , Ácido Eicosapentaenoico/sangue , Eritrócitos/efeitos dos fármacos , Ácidos Graxos Ômega-3/administração & dosagem , Pré-Menopausa/sangue , Adulto , Método Duplo-Cego , Contagem de Eritrócitos , Feminino , HumanosRESUMO
OBJECTIVES: To investigate the effect of oral zinc supplementation on cervicovaginal lavage fluid (CVL) zinc level in pre and postmenopausal women. STUDY DESIGN: A prospective interventional cohort study was carried out by the enrollment of twelve premenopausal and ten postmenopausal women without significant gynecological conditions. Women received daily oral supplementation with 30 mg of zinc for two weeks. Clinical and demographic variables were stored in a dedicated database. Vaginal Health Index was calculated, and vaginal cytology was obtained. CVL and serum samples were collected in a standardized fashion before and after completion of the oral supplementation. Zinc and copper levels were measured by inductively coupled plasma optical emission spectrometry. Paired t-test was used to compare the before and after treatment results. RESULTS: Serum zinc levels increased significantly both in the pre and postmenopausal women (0.88 ± 0.17 vs. 1.06 ± 0.23, p < 0.01 and 0.83 ± 0.24 vs. 0.96 ± 0.33, p < 0.01) after two weeks of daily oral zinc supplementation. CVL zinc level was significantly higher in the premenopausal group compared to the postmenopausal group before and after supplementation (0.13 ± 0.05 vs. 0.06 ± 0.04, p < 0.01 and 0.10 ± 0.03 vs. 0.05 ± 0.01, p < 0.01). Zinc supplementation had no significant impact on the CVL zinc level in either group. Neither serum nor CVL copper levels were affected by the zinc supplementation. There was no significant correlation between serum and CVL zinc or copper levels. CONCLUSION: Daily oral supplementation with 30 mg of zinc had no significant impact on CVL zinc level despite a significant rise in serum zinc level.
Assuntos
Vagina/metabolismo , Zinco/administração & dosagem , Administração Oral , Adulto , Líquidos Corporais/efeitos dos fármacos , Cobre/análise , Suplementos Nutricionais , Feminino , Humanos , Pessoa de Meia-Idade , Pós-Menopausa/sangue , Pré-Menopausa/sangue , Estudos Prospectivos , Método Simples-Cego , Vagina/efeitos dos fármacos , Esfregaço Vaginal/métodos , Zinco/análise , Zinco/sangueRESUMO
OBJECTIVE: The aim of this study was to investigate the effects of cholecalciferol supplementation on serum levels of angiogenic parameters in patients with breast cancer (BC) who were treated with tamoxifen. METHODS: This was a pilot-based, randomized, triple-blind, placebo-controlled clinical trial with 52 patients with BC randomly assigned to either an intervention group receiving weekly 50 000 IU cholecalciferol or a placebo group for 8 wk. At baseline and at end of study, serum levels of angiogenic growth factors such as vascular endothelial growth factor (VEGF)-A, angiopoietin (Ang)-2, hypoxia-inducible factor (Hif)-1, and high-sensitivity C-reactive protein were measured by enzyme-linked immunosorbent assay. Every 4 wk, a completed 3-d, 24-h dietary record and daily sunlight exposure checklist were collected and anthropometric variables were measured. RESULTS: The ultimate number of participants in each arm was 22 for analyses. For premenopausal women, cholecalciferol supplementation resulted in a significant decrease in serum levels of Ang-2 and VEGF-A after 8 wk of treatment (P < 0.05). In the absence of vascular invasion, supplementation led to a significant decrease in Ang-2 levels compared with the placebo group (P < 0.05). Supplementation caused significant increases in Hif-1 in patients diagnosed with the infiltration of tumors into vascular or lymphatic vessels (P < 0.05). CONCLUSION: Cholecalciferol supplementation achieved sufficient efficacy among patients with BC taking tamoxifen and could be effective in the reduction of angiogenic biomarkers particularly dependent on the infiltration status of the tumor to vessels. Further studies with larger subgroups should be investigated.
Assuntos
Angiopoietina-2/sangue , Neoplasias da Mama/sangue , Colecalciferol/administração & dosagem , Suplementos Nutricionais , Fator A de Crescimento do Endotélio Vascular/sangue , Vitaminas/administração & dosagem , Adulto , Antineoplásicos Hormonais , Biomarcadores/sangue , Neoplasias da Mama/terapia , Método Duplo-Cego , Feminino , Humanos , Fator 1 Induzível por Hipóxia/sangue , Pessoa de Meia-Idade , Projetos Piloto , Pós-Menopausa/sangue , Pré-Menopausa/sangue , Projetos de Pesquisa , Tamoxifeno/uso terapêuticoRESUMO
BACKGROUND AND AIMS: Low vitamin D (vitD) has been linked to increased cardiovascular (CV) risk, but the effects of vitD supplementation are not clarified. We evaluated the impact of vitD normalization on HDL cholesterol efflux capacity (CEC), which inversely correlates with CV risk, the proatherogenic serum cholesterol loading capacity (CLC), adipokine profile and subclinical atherosclerosis. METHODS AND RESULTS: Healthy premenopausal women with vitD deficiency (n = 31) underwent supplementation. Subclinical atherosclerosis was evaluated by flow-mediated dilation (FMD), pulse wave velocity (PWV) and augmentation index (AIx), measured with standard techniques. HDL CEC and serum CLC were measured by a radioisotopic and fluorimetric assay, respectively. Malondialdehyde (MDA) in HDL was quantified by the TBARS assay. Pre-ß HDL was assessed by 2D-electrophoresis. Serum adipokines were measured by ELISA. VitD replacement restored normal levels of serum 25-hydroxyvitamin D (25OHD) and significantly improved FMD (+4%; p < 0.001), PWV (-4.1%: p < 0.001) and AIx (-16.1%; p < 0.001). Total CEC was significantly improved (+19.5%; p = 0.003), with a specific increase in the ABCA1-mediated CEC (+70.8%; p < 0.001). HDL-MDA slightly but significantly decreased (-9.6%; p = 0.027), while no difference was detected in pre-ß HDL. No change was observed in aqueous diffusion nor in the ABCG1-mediated CEC. Serum CLC was significantly reduced (-13.3%; p = 0.026). Levels of adiponectin were increased (+50.6%; p < 0.0001) and resistin levels were decreased (-24.3%; p < 0.0001). After vitD replacement, an inverse relationship was found linking the ABCA1-mediated CEC with pre-ß HDL (r2 = 0.346; p < 0.001) and resistin (r2 = 0.220; p = 0.009). CONCLUSION: Our data support vitD supplementation for CV risk prevention.
Assuntos
Adipocinas/sangue , Aterosclerose/prevenção & controle , Colecalciferol/administração & dosagem , HDL-Colesterol/sangue , Suplementos Nutricionais , Lipoproteínas de Alta Densidade Pré-beta/sangue , Pré-Menopausa/sangue , Deficiência de Vitamina D/tratamento farmacológico , Transportador 1 de Cassete de Ligação de ATP/metabolismo , Adulto , Doenças Assintomáticas , Aterosclerose/sangue , Aterosclerose/diagnóstico , Aterosclerose/etiologia , Biomarcadores/sangue , Colecalciferol/efeitos adversos , Suplementos Nutricionais/efeitos adversos , Feminino , Humanos , Estudo de Prova de Conceito , Resistina/sangue , Fatores de Tempo , Resultado do Tratamento , Turquia , Vitamina D/análogos & derivados , Vitamina D/sangue , Deficiência de Vitamina D/sangue , Deficiência de Vitamina D/complicações , Deficiência de Vitamina D/diagnósticoRESUMO
BACKGROUND Mild moxibustion has been reported to effectively treat menopausal syndrome. This study investigated the efficacy and safety of using mild moxibustion at Shenshu for treating sub-health states in perimenopausal women. MATERIAL AND METHODS Sixty participants were randomly assigned to moxibustion and control groups. Participants in the moxibustion group received mild moxibustion at bilateral Shenshu (BL23) for 15 min daily. A course was 5 days, with 2 days between courses; treatment was conducted for 4 courses. Participants in the control group were given vitamin E soft capsules for 28 days. Physical condition, living conditions, emotional status, and energy status scores were assessed, and serum sex hormone levels measured. RESULTS Mild moxibustion significantly improved physical condition, living conditions, and emotional status compared to the control group after treatment ([i]P[/i]<0.05). Physical condition ([i]P[/i]<0.01) and living conditions ([i]P[/i]<0.05) improved significantly in post-menopausal women, while living conditions and emotional status were improved in pre-menopausal women ([i]P[/i]<0.05). Serum estradiol level was significantly higher after moxibustion, especially for pre-menopausal women ([i]P[/i]<0.01). CONCLUSIONS Mild moxibustion is safe and effective for treating sub-health state in pre-menopausal and post-menopausal women. A study with larger sample size and longer-term treatment is needed for further assessment of this topic.
Assuntos
Moxibustão , Pós-Menopausa/fisiologia , Pré-Menopausa/fisiologia , Estudos de Casos e Controles , Feminino , Hormônios Esteroides Gonadais/sangue , Humanos , Pessoa de Meia-Idade , Moxibustão/efeitos adversos , Pós-Menopausa/sangue , Pré-Menopausa/sangue , Resultado do TratamentoRESUMO
The study aimed to explore determinants of bone parameters in young women. Most bone parameters were associated with height and lean mass. Bone parameters were not associated with vitamin D status. Future research should address whether interventions aimed at improving lean mass are beneficial to bone health in young women. INTRODUCTION: The implementation of prevention strategies during young adulthood may be crucial for osteoporosis prevention in later life, yet literature examining the determinants of bone health in premenopausal women is limited. We aimed to assess determinants of bone health, including serum 25-hydroxyvitamin D (25OHD), in females aged 16-25 years, living in Victoria, Australia, recruited through Facebook advertising. METHODS: Serum 25OHD was measured by liquid chromatography-tandem mass spectrometry and bone health was measured using dual-energy X-ray absorptiometry (DXA) and peripheral quantitative computed tomography (pQCT) in 326 participants. RESULTS: Mean (± standard deviation) serum 25OHD was 69 ± 28 nmol/L and the prevalence of vitamin D deficiency (serum 25OHD <50 nmol/L) was 26%. Seven percent of participants (n = 23) reported taking a vitamin D supplement. Two percent of participants had low lumbar spine bone mineral density (Z-score <-2.0), 5% at the hip and 7% at the femoral neck. Serum 25OHD levels were not associated with DXA bone parameters, nor with pQCT bone parameters. Most bone parameters were positively associated with height and lean mass. CONCLUSION: Vitamin D status was not associated with bone health in young women in the current study. Our findings suggest that targeting other modifiable factors, such as lean body mass, is likely to be beneficial to bone health in young women. Longitudinal studies examining the association between vitamin D status and bone health in young women are necessary to confirm our findings. In addition, whether raising 25OHD levels is advantageous for young women's bone health is yet to be determined.
Assuntos
Densidade Óssea/fisiologia , Vitamina D/análogos & derivados , Absorciometria de Fóton/métodos , Adolescente , Adulto , Antropometria/métodos , Estatura/fisiologia , Feminino , Colo do Fêmur/fisiologia , Articulação do Quadril/fisiologia , Humanos , Estilo de Vida , Vértebras Lombares/fisiologia , Hormônio Paratireóideo/sangue , Pré-Menopausa/sangue , Pré-Menopausa/fisiologia , Prevalência , Tomografia Computadorizada por Raios X/métodos , Vitória/epidemiologia , Vitamina D/sangue , Deficiência de Vitamina D/sangue , Deficiência de Vitamina D/epidemiologia , Deficiência de Vitamina D/fisiopatologia , Adulto JovemRESUMO
In cell culture studies, dried plum (Prunus domestica L.) polyphenols increased osteoblast alkaline phosphatase (ALP) activity, mineralized nodule formation, and the expression of the bone marker genes runt-related transcription factor 2 (RUNX2) and osterix. The purpose of this study was to determine whether human serum collected 1 and 2 h after dried plum ingestion influenced osteoblast cell activity and gene expression. Five healthy women ingested 100 g of dried plum, and serum samples were collected at baseline (before dried plum ingestion) and 1 and 2 h postingestion of dried plum. MC3T3-E1 osteoblast cells were treated (2% of medium) with these serum samples for 3 or 9 days. Intracellular and extracellular ALP activities were significantly increased after 3 or 9 days of treatment with serum both postingestion time points, with no effect seen in baseline samples. Also, serum obtained 1 and 2 h postingestion significantly increased the mRNA expression of bone markers RUNX2 and connexin43 (CX43) after both 3 and 9 days of incubation periods. Finally, serum obtained 1 and 2 h postingestion increased the mRNA expression of ß-catenin after 9 days of incubation. We conclude that osteoblast activity and function are increased by dried plum ingestion, which may, in part, explain its beneficial effects on bone health.
Assuntos
Diferenciação Celular , Osteoblastos/citologia , Pré-Menopausa/metabolismo , Prunus domestica/metabolismo , Adulto , Fosfatase Alcalina/metabolismo , Animais , Conexina 43/genética , Conexina 43/metabolismo , Subunidade alfa 1 de Fator de Ligação ao Core/sangue , Feminino , Humanos , Camundongos , Osteoblastos/enzimologia , Osteoblastos/metabolismo , Pré-Menopausa/sangue , Fator de Transcrição Sp7 , Fatores de Transcrição/sangue , beta Catenina/metabolismoRESUMO
OBJECTIVE: Vitamin D deficiency has been linked to a higher risk of cancer. There is insufficient data regarding the influence of treatment on vitamin D status. The aim of this study was to compare pre- and post-treatment levels of 25(OH)D in premenopausal and postmenopausal women with breast cancer with a different receptor status (ER-estrogen receptors, PR-progesterone receptors) and in healthy controls. METHODS: 49 patients with breast cancer (23 premenopausal), and 28 healthy controls matched for age, menopausal status and BMI. RESULTS: The pre-treatment levels of 25(OH)D in patients with breast cancer were significantly lower in comparison to the control group (19 ng/mL vs. 30 ng/mL, p<0.001), the lowest in premenopausal women (18.4 ng/mL). After the treatment period, a significant decrease in 25(OH)D level (mean 15.8 ng/mL) was observed. The pre-treatment level of 25(OH)D was significantly lower in patients with ER (16.1 vs. 23.9 ng/mL, p=0.02) and with PR (15 vs. 24.4 ng/mL, p=0.003). The mean pre- and post-treatment levels of 25(OH)D were lower in patients with Ki67 <21% (16.7 vs. 20.1 ng/mL, p=0.15; 12.5 vs. 18.1 ng/mL, p=0.02 respectively). CONCLUSIONS: 25(OH)D level is lower in patients with breast cancer in comparison to healthy women, regardless of their menopausal status. The lowest levels are found in patients with ER and PR positive tumours. While a significant decrease in 25(OH)D level during the course of therapy is observed, the supplementation of vitamin D should be considered.
Assuntos
Neoplasias da Mama/terapia , Pós-Menopausa/sangue , Pré-Menopausa/sangue , Vitamina D/análogos & derivados , Neoplasias da Mama/sangue , Neoplasias da Mama/metabolismo , Neoplasias da Mama/patologia , Feminino , Humanos , Receptores de Estrogênio/metabolismo , Receptores de Progesterona/metabolismo , Vitamina D/sangueRESUMO
BACKGROUND: Many factors, such as heredity, ethnicity, nutrition and other lifestyle factors, have been related to bone mineral density in postmenopausal women. Additionally, bone mass has been significantly associated with decreased estrogen levels. However, fewstudies have been conducted on premenopausal women. The present study was designed to estimate the relationship between low bone mineral density and levels of serum estradiol and lifestyle factors in premenopausal Mexican women. METHODS: A cross-sectional study was conducted in 270 women between 40 and 48 years of age who participate in the Health Workers Cohort Study. Information on socio-demographic and lifestyle factors were obtained through a self-administered questionnaire. Body mass index and serum estradiol were measured with standard procedures; bone mineral density was assessed using dual-energy X-ray absorptiometry. Multiple linear and logistic regression models were computed to evaluate the relationship between low bone mineral density and levels of serum estradiol and lifestyle factors. RESULTS: In linear regression analysis levels of estradiol, body mass index, physical activity, and vitamin D intake were positively related to bone mineral density. Age, cigarette smoking and caffeine were inversely associated with BMD. Finally, the odds of low bone mineral density increase significantly when the premenopausal women had low levels of serum estradiol (OR = 4.93, 95 % CI: 2.14, 11.37). CONCLUSION: These data support that low serum estradiol, advancing age, lower physical activity, lower vitamin D intake, cigarette smoking, and higher amount of caffeine intake are linked to low bone mineral density in premenopausal Mexican women.
Assuntos
Densidade Óssea , Estradiol/sangue , Estilo de Vida , Osteoporose/sangue , Pré-Menopausa/sangue , Absorciometria de Fóton , Adulto , Fatores Etários , Índice de Massa Corporal , Cafeína/efeitos adversos , Cálcio da Dieta/administração & dosagem , Estudos de Coortes , Estudos Transversais , Suplementos Nutricionais , Exercício Físico , Feminino , Humanos , México , Pessoa de Meia-Idade , Fumar/efeitos adversos , Inquéritos e Questionários , Vitamina D/administração & dosagemRESUMO
BACKGROUND/PURPOSE: Low levels of vitamin D may play a role in the pathogenesis of psoriasis and is related to increased risk of osteoporosis. There are a few studies showing increased rate of osteoporosis in patients with psoriasis; however, none of them investigated impact of vitamin D levels and gender status together. We aimed to evaluate relationship between vitamin D and osteoporosis in psoriasis patients with an emphasis on gender difference. METHODS: Forty-three psoriasis patients without arthritis and 41 healthy controls were enrolled. All patients were <50 years, and women were premenopausal. Participants were questioned about demographic features, sun exposure, regular physical exercise, and smoking status. The serum levels of 25-OH vitamin D, calcium, phosphorus, C-reactive protein, parathyroid hormone, total alkaline phosphatase, and sedimentation rate were measured. Body mass index was calculated. We determined the bone mineral density of the lumbar spine and femur using dual-energy X-ray absorptiometry. RESULTS: Femur neck Z score and lumbar spine total Z score were lower in psoriasis group than those of the control group. Additionally, total femoral Z score, lumbar spine total T, and Z scores were lower in female patients with psoriasis than female controls, whereas for male subjects there was not a remarkable difference between the groups. There was no significant difference between the two groups regarding vitamin D levels. The latter was significantly lower in psoriasis group than in controls for females; however, there was no significant difference between the two groups of males. Patients with psoriasis had higher CRP level and sedimentation rate, than control subjects. Female patients had also higher CRP level and sedimentation rate, than female controls, but there were no significant differences between male patients and controls. CONCLUSION: As osteoporosis has multifactorial etiology, psoriasis may be among the triggering or facilitating factors for osteoporosis particularly in psoriatic women via several mechanisms such as low blood level of vitamin D and increased inflammation.
Assuntos
Densidade Óssea , Inflamação/sangue , Psoríase/sangue , Vitamina D/análogos & derivados , Absorciometria de Fóton , Adulto , Fosfatase Alcalina/sangue , Sedimentação Sanguínea , Proteína C-Reativa/metabolismo , Cálcio/sangue , Estudos de Casos e Controles , Feminino , Colo do Fêmur/diagnóstico por imagem , Humanos , Vértebras Lombares/diagnóstico por imagem , Masculino , Pessoa de Meia-Idade , Hormônio Paratireóideo/sangue , Fósforo/sangue , Pré-Menopausa/sangue , Fatores Sexuais , Vitamina D/sangueRESUMO
CONTEXT: Biomarkers to predict bone loss in premenopausal women after breast cancer treatment have not been examined. OBJECTIVE: To determine whether baseline FSH predicts subsequent bone loss. DESIGN: Secondary data analysis of the Exercise for Bone Health: Young Breast Cancer Survivors study, in which women were randomized to a 12-month exercise program or monthly health newsletter. SETTING: Community dwelling women. PARTICIPANTS: A total of 206 women age less than or equal to 55 years at breast cancer diagnosis who had received adjuvant chemotherapy and were at least 1 year after diagnosis. INTERVENTION: Serum collected at baseline (an average of 302 ± 148 d after completing chemotherapy) was analyzed for FSH. MAIN OUTCOME MEASURE: Change in bone mineral density. RESULTS: In linear regression models, baseline FSH levels predicted bone loss over the ensuing 12 months at the lumbar spine and femoral neck including after adjustment for age, ethnicity, treatment group (exercise vs control), baseline bone density, and high-sensitivity C-reactive protein (P < .001). In multiply adjusted models, the 12-month rate of change in bone density was +0.007% in the lowest tertile of FSH (FSH = 9 ± 7 IU/L, mean ± SD), -0.96% in the middle tertile (mean FSH = 41 ± 11 IU/L), and -2.2% in the highest tertile (mean FSH = 86 ± 19 IU/L), P for trend <.001. CONCLUSIONS: Among premenopausal women with breast cancer treated with chemotherapy, baseline FSH levels are strongly associated with subsequent bone loss. Further studies are needed to establish the optimal timing of FSH measurement in relation to breast cancer treatment and to investigate potential strategies to prevent bone loss.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Doenças Ósseas Metabólicas/diagnóstico , Neoplasias da Mama/tratamento farmacológico , Hormônio Foliculoestimulante/sangue , Pré-Menopausa/sangue , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Densidade Óssea/efeitos dos fármacos , Doenças Ósseas Metabólicas/sangue , Doenças Ósseas Metabólicas/epidemiologia , Doenças Ósseas Metabólicas/prevenção & controle , Neoplasias da Mama/sangue , Neoplasias da Mama/epidemiologia , Neoplasias da Mama/reabilitação , Quimioterapia Adjuvante/efeitos adversos , Terapia por Exercício , Feminino , Humanos , Pessoa de Meia-Idade , Pré-Menopausa/efeitos dos fármacos , Insuficiência Ovariana Primária/sangue , Insuficiência Ovariana Primária/induzido quimicamente , Insuficiência Ovariana Primária/complicações , Insuficiência Ovariana Primária/epidemiologia , PrognósticoRESUMO
UNLABELLED: We used bone turnover markers to identify women who responded to bisphosphonate treatment for osteoporosis. Response was more likely with alendronate and ibandronate than risedronate. There was a greater decrease in bone markers if baseline bone turnover markers were higher and if the patient took more than 80 % of her medication. INTRODUCTION: Biochemical response to bisphosphonate therapy can be assessed using either a decrease in bone turnover marker beyond the least significant change (LSC) or a reduction to within a reference interval (RI). We compared the performance of these target responses and determined whether response was related to the type of bisphosphonate, compliance and baseline bone turnover markers. METHODS: Biochemical responses to three oral bisphosphonates were assessed in an open, controlled trial comprising 172 postmenopausal osteoporotic women (age 53-84 years), randomised to alendronate, ibandronate or risedronate, plus calcium and vitamin D supplementation for 2 years. The LSC for each marker was derived within the study population, whereas RIs were obtained from a control group of healthy premenopausal women (age 35-40 years). RESULTS: Over 70 % of women achieved a target response for serum CTX and PINP, irrespective of the approach used. The percentage decrease at 12 weeks was greater for women with baseline PINP above the RI -63 % (difference 13 %, 95 % CI 0 to 27.1, P = 0.049) and good compliance -67 % (difference 15.9 %, 95 % CI 6.3 to 25.5, P = 0.001). Responders had a greater increase in spine bone density compared to nonresponders; for example 6.2 vs. 2.3 % (difference 3.9 %, 95 % CI 1.6 to 6.3, P = 0.0011) for PINP LSC. The magnitude of change in bone markers was greater with ibandronate and alendronate than risedronate. CONCLUSIONS: Both approaches to response identified similar proportions of women as responders. Nonresponders had smaller increases in BMD, and we suggest that biochemical assessment of response is a useful tool for the management of women with postmenopausal osteoporosis.
Assuntos
Conservadores da Densidade Óssea/uso terapêutico , Remodelação Óssea/efeitos dos fármacos , Difosfonatos/uso terapêutico , Osteoporose Pós-Menopausa/tratamento farmacológico , Administração Oral , Adulto , Idoso , Idoso de 80 Anos ou mais , Alendronato/administração & dosagem , Alendronato/farmacologia , Alendronato/uso terapêutico , Biomarcadores/sangue , Densidade Óssea/efeitos dos fármacos , Densidade Óssea/fisiologia , Conservadores da Densidade Óssea/administração & dosagem , Conservadores da Densidade Óssea/farmacologia , Remodelação Óssea/fisiologia , Difosfonatos/administração & dosagem , Difosfonatos/farmacologia , Feminino , Humanos , Ácido Ibandrônico , Vértebras Lombares/fisiopatologia , Pessoa de Meia-Idade , Osteoporose Pós-Menopausa/fisiopatologia , Pré-Menopausa/sangue , Valores de Referência , Ácido Risedrônico/administração & dosagem , Ácido Risedrônico/farmacologia , Ácido Risedrônico/uso terapêutico , Resultado do TratamentoRESUMO
OBJECTIVE: To investigate whether a supplement of 2.2g of marine n-3 polyunsaturated fatty acids (PUFA) influences plasma proprotein convertase subtilisin kexin type 9 (PCSK9) levels in pre- and postmenopausal women. METHODS: Ninety-two healthy women were randomly assigned to consume 2.2g marine n-3 PUFA or a control oil (thistle oil) daily for 12 weeks. Adipose tissue, a long-term marker of dietary intake of seafood was collected at baseline and blood samples were drawn at baseline and after 12 weeks of supplement intake. RESULTS: Plasma PCSK9 levels were significantly reduced by 11.4% for premenopausal women and 9.8% for postmenopausal women after the supplement of 2.2g of marine n-3 PUFA compared with control oil. The mean change of plasma PCSK9 levels between participants receiving marine n-3 PUFA and control oil was 16.1% for premenopausal women and 13.1% for postmenopausal women. There was, however, no correlation between baseline levels of plasma PCSK9 and the fatty acid content of marine n-3 PUFA in adipose tissue. CONCLUSION: This study showed that 2.2g marine n-3 PUFA reduce plasma PCSK9 levels in both pre- and postmenopausal women.
Assuntos
Ácidos Graxos Ômega-3/administração & dosagem , Pós-Menopausa/sangue , Pré-Menopausa/sangue , Pró-Proteína Convertases/sangue , Serina Endopeptidases/sangue , Tecido Adiposo/efeitos dos fármacos , Tecido Adiposo/metabolismo , Adulto , Animais , Biomarcadores/sangue , Suplementos Nutricionais , Método Duplo-Cego , Feminino , Humanos , Camundongos , Pessoa de Meia-Idade , Óleos/administração & dosagem , Pró-Proteína Convertase 9RESUMO
BACKGROUND: Complex metabolic changes cause obesity, making weight loss difficult. For this reason, understanding metabolism is important, and considering the shortcomings of conventional treatment options for obesity, acupuncture is a possible option. However, evidence supporting its efficacy on metabolic parameters in obese patients is lacking. The aim of this study is to investigate the effects of acupuncture on serum metabolic parameters in premenopausal obese women. METHODS/DESIGN: This ongoing study is a randomized, patient-assessor blind, two-arm parallel non-penetrating sham-controlled clinical trial. Eligible participants, premenopausal adult women (19 years of age or older) with a clinical diagnosis of obesity (body mass index of 25 kg/m(2) or more) blinded to the treatment received, will be randomly allocated blindly into the real acupuncture treatment group (manual acupuncture plus electroacupuncture, n = 60) or the sham acupuncture control group (sham acupuncture plus placebo acupuncture without electrical stimulation, n = 60) and receive treatment two times a week for a total of 12 sessions over 6 weeks. The primary outcome measure is the serum cholesterol and triglyceride (TG) levels at baseline and endpoint. The secondary outcomes are body weight, body fat mass, muscle mass, waist and hip circumference, other serum metabolic profiles, International Physical Activity Questionnaire (IPAQ), Social Readjustment Rating Scale (SRRS), Stress Response Inventory (SRI), Fatigue Severity Scale (FSS), the Korean version of the Beck Depression Inventory (BDI), and urine metabolites. Adverse events will be assessed at every visit. DISCUSSION: The results of this trial (which will be available in 2015) will provide important clinical evidence for the effect of acupuncture on serum metabolites and demonstrate how acupuncture can be helpful for the treatment of obesity. TRIAL REGISTRATION: Trial registration registered via US National Institutes of Health Clinical Trials registry (ClinicalTrials.gov) on 11 November 2014, identifier: NCT02066090 .
Assuntos
Terapia por Acupuntura , Colesterol/sangue , Obesidade/terapia , Pré-Menopausa/sangue , Triglicerídeos/sangue , Terapia por Acupuntura/efeitos adversos , Adiposidade , Adulto , Fatores Etários , Antropometria , Biomarcadores/sangue , Índice de Massa Corporal , Protocolos Clínicos , Feminino , Humanos , Metabolômica/métodos , Obesidade/sangue , Obesidade/diagnóstico , Obesidade/fisiopatologia , República da Coreia , Projetos de Pesquisa , Fatores Sexuais , Inquéritos e Questionários , Fatores de Tempo , Resultado do Tratamento , Adulto JovemRESUMO
BACKGROUND/OBJECTIVES: A relationship between osteocalcin (OC) levels and factors associated with energy metabolism and insulin resistance has been reported recently. The aim of this study was to investigate whether modulation of ostecalcin isoforms via vitamin K1 supplementation would affect glucose metabolism or insulin sensitivity in prediabetic and premenopause women. SUBJECTS/METHODS: Eighty-two prediabetic women were randomized to consume vitamin K1 supplement (n = 39) or placebo (n = 43) for 4 weeks. Participants in the vitamin K1 supplement group received one pearl softgel capsule containing 1000 µm of phylloquinone, and the placebo group received one placebo capsule daily for 4 weeks. Blood samples were collected at baseline and after the 4-week intervention period to quantify carboxylated OC (cOC), undercarboxylated OC (ucOC) and relevant variables. RESULTS: Phylloquinone supplementation increased the serum levels of cOC and decreased ucOC, compared with placebo (12.53 ± 5.95 compared with 7.43 ± 4.85 ng/ml and 2.47 ± 1.91 compared with 4.79 ± 2.43 ng/ml, respectively; P < 0.001). Furthermore, intake of phylloquinone supplement led to significant decreases in %ucOC (17.97 ± 12.24 compared with 43.80 ± 19.86) and 2-h post-oral glucose tolerance test (OGTT) glucose (7.32 ± 1.50 compared with 8.62 ± 1.45 mmol/l), and 2-h post-OGTT insulin level (80.34 ± 42.24 compared with 112.43 ± 53.19 µIU/ml) and increased insulin sensitivity index (2.46 ± 0.71 compared with 1.75 ± 0.61) compared with placebo. Overall, a significant association was found between changes in %ucOC and changes in 2-h post-OGTT glucose (r = 0.308, P = 0.028). CONCLUSIONS: The results of this study demonstrated that vitamin K1 supplementation for 4 weeks did not affect insulin resistance in premenopausal and prediabetic women but had beneficial effects on glycemic status and insulin sensitivity.
Assuntos
Resistência à Insulina/fisiologia , Osteocalcina/sangue , Estado Pré-Diabético/tratamento farmacológico , Vitamina K 1/farmacologia , Adulto , Glicemia/análise , Suplementos Nutricionais , Método Duplo-Cego , Feminino , Teste de Tolerância a Glucose , Humanos , Insulina/sangue , Pessoa de Meia-Idade , Estado Pré-Diabético/sangue , Pré-Menopausa/sangue , Adulto JovemRESUMO
Endocrine therapy (ET) is a key treatment modality in hormone receptor positive (HR+) early breast cancer (BC) patients. Although the anticancer activity of adjuvant ET + zoledronic acid (ZOL) has been investigated, the potential effects of ET ± ZOL on endocrine hormones in premenopausal women with HR+ early BC are not well understood. ProBONE II was prospective, double-blind, randomized controlled trial. Premenopausal patients with histologically confirmed invasive BC with no evidence of metastases and a T score >-2.5 received ET ± ZOL 4 mg every 3 months for 2 years. Serum levels of estradiol (E2), follicle-stimulating hormone, anti-muellerian hormone (AMH), inhibins A and B, sex hormone-binding globulin, parathyroid hormone, total testosterone, and vitamin D were evaluated at baseline and at every scheduled visit. Of 71 women enrolled, 70 were evaluable (n = 34, ZOL; n = 36, placebo). No statistically significant differences were observed in hormone levels, except E2 and AMH, which showed minor differences. These included decreases in serum E2 levels, which reached a nadir after 3 and 9 months in placebo and ZOL groups, respectively, and decrease in serum AMH levels throughout the study with ZOL, but remained constant with placebo after 6 months. Adverse events in ZOL-treated group were influenza-like illness (32.4 %), bone pain (32.4 %), chills (20.6 %), and nausea (23.5 %). ET ± ZOL was well tolerated. This study showed no influence of ZOL on hormonal level changes that accompany ET, supporting inclusion of ZOL in adjuvant therapy for premenopausal women with HR + BC.